OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Michael Kuchenreuther, PhD, is a research analyst, at Numerof & Associates, Inc.
April 29, 2016
Immuno-oncology drugs are demonstrating patient benefits, but growing resistance to the high cost has implications for patients, market access, and manufacturers.
December 02, 2015
The author provides an overview of the key aspects of the current Canadian pharmaceutical market.
October 26, 2015
The authors look at key factors driving the risk-sharing agreements that have been implemented to reduce drug expenditures across Europe.
August 01, 2015
China’s emergence as a significant commercial market is forcing manufacturers to re-evaluate their overall business model.
July 02, 2015
With the French pricing and reimbursement policies becoming increasingly stringent, pharmaceutical manufacturers must adapt their drug development and commercial strategies if they want to secure premium pricing for their new products.
January 02, 2015
Bio/pharmaceutical manufacturers in the UK face challenges in proving that their drugs are worth the price.